Aphton Corporation (APHT) Reports Activity Of IGN101 In Reducing Disseminating Tumor Cells From Patients With Epithelial Cancers
10/19/2005 5:10:07 PM
PHILADELPHIA--(BUSINESS WIRE)--May 16, 2005--
Early Data Demonstrated Reduction of Disseminating Tumor in Patients With Cancers of the Colon, Breast and Ovary
Aphton Corporation (NASDAQ:APHT) announced today that preliminary data from an ongoing open-label, multicenter Phase II clinical trial with IGN101 in patients with several types of solid tumors was presented on Sunday at the 2005 Annual Meeting of the American Society for Clinical Oncology (ASCO) in Orlando, Florida.
Investigators presented early data from an ongoing single arm study of IGN101 in patients with various solid tumors. The study, which is intended to accrue 45 patients, has enrolled 17 patients to date. The primary objective of the trial is to assess the ability of IGN101 to decrease circulating tumor cells in peripheral blood. Elevation of circulating tumor cells has been shown to predict short survival in multiple types of cancer, including breast cancer and hormone refractory prostate cancer. Secondary objectives of the trial are the evaluation of safety and tolerability. Vaccinations with IGN101 are given by subcutaneous injection on days 1, 15, 29 and 57. Analyses of circulating tumor cells in peripheral blood were performed on days 1, 29, 57 and 71.
comments powered by